Mochida Pharmaceutical: Independent Company Executives Declaration
Mochida Pharmaceutical: Humanized anti-human IL-23p19 monoclonal antibody “onbo subcutaneous injection autoinjector, subcutaneous injection syringe” can now be self-injected at home
Mochida Pharmaceutical: Notice of the 86th Annual General Meeting of Shareholders in 2024
Mochida Pharmaceutical: 2024 Annual General Meeting of Shareholders and other electronic provision measures (issuance documents omitted)
Mochida Pharmaceutical: 2024 Annual General Meeting of Shareholders Convocation Notice
Mochida Pharmaceutical: [Summary] Consolidated financial results for the fiscal year ended 2024/3/31
Mochida Pharmaceutical: Notice regarding changes in officers
Mochida Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Mochida Pharmaceutical: Treasury Stock Purchase Status Report (based on Section 24-6 (1) of the Act)
Mochida Pharmaceutical: Notice of conclusion of an agreement relating to the sale of Epadale in China
Mochida Pharmaceutical: Notice regarding the status and completion of share buybacks
Mochida Pharmaceutical: Treasury stock purchase status report (based on Act Section 24-6 (1))
Mochida Pharmaceutical: Notice of personnel changes
Mochida Pharmaceutical: Notice regarding status of share repurchases
Mochida Pharmaceutical: Notice regarding cancellation of treasury stock
Mochida Pharmaceutical: Confirmation
Mochida Pharmaceutical: Quarterly Report - 86th Term 3rd Quarter (2023/10/01 - 2023/12/31)
Mochida Pharmaceutical: Treasury Stock Purchase Status Report (based on Section 24-6 (1) of the Act)
Mochida Pharmaceutical: [Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2023
Mochida Pharmaceutical: Notice regarding revisions to earnings forecasts
No Data